RxDoctor Payments Data

Bethany Stough

Family · State College, PANPI 1154814002

Payments from drug & device makers

$1,022in general payments, 2019–2025

Across 36 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$249
  • Novo Nordisk$221
  • E.r. Squibb & Sons, L.L.C.$120
  • Pfizer$97
  • Biohaven Pharmaceuticals, Inc.$85
  • Sanofi$85
  • plus $165 from 5 others

What the payments were for

  • Food & beverage$1,022100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,022 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,698
Medicare patients
110
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$144,259
EliquisApixaban103$90,347
JardianceEmpagliflozin69$60,960
MounjaroTirzepatide46$56,258
TrulicityDulaglutide34$47,282
JanuviaSitagliptin Phosphate39$32,954
MyrbetriqMirabegron50$30,934
XareltoRivaroxaban29$27,972
RybelsusSemaglutide30$26,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$25,273
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$17,922
LinzessLinaclotide18$13,057
Fluticasone-SalmeterolFluticasone Propion/Salmeterol47$9,088
Repatha SyringeEvolocumab14$7,535
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$6,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$221$170,957173 claims
Lilly USA, LLCMounjaro, Trulicity$249$103,54080 claims
PfizerEliquis$97$90,347103 claims
GSKTrelegy Ellipta, Breo Ellipta$49$30,07849 claims
AbbVieLinzess$56$13,05718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →